TREATMENT OF BRAZILIAN KALA-AZAR WITH A SHORT-COURSE OF AMPHOCIL (AMPHOTERICIN-B CHOLESTEROL DISPERSION)

被引:57
作者
DIETZE, R
MILAN, EP
BERMAN, JD
GROGL, M
FALQUETO, A
FEITOSA, TF
LUZ, KG
SUASSUNA, FAB
MARINHO, LAC
KSIONSKI, G
机构
[1] FED UNIV ESPIRITO SANTO,TROP MED UNIT,VITORIA,ES,BRAZIL
[2] FED UNIV RIO GRANDE NORTE,HOSP GISELDA TRIGUEIRO,DEPT TROP & INFECT DIS,NATAL,RN,BRAZIL
[3] LIPOSOME TECHNOL,MENLO PK,CA
基金
英国惠康基金;
关键词
D O I
10.1093/clinids/17.6.981
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Amphotericin B is an effective but toxic antileishmanial agent. Lipid-encapsulated amphotericin B should have a high therapeutic index for visceral leishmaniasis because reticuloendothelial cells, the sole site in which Leishmania is found, will phagocytize and concentrate the complex. Amphotericin B cholesterol dispersion (Amphocil; 2 mg/[kg.d] intravenously) was administered to 10 Brazilians with kala-azar for 10 days (cohort 1) and to 10 Brazilians with kala-azar for 7 days (cohort 2). All patients were successfully treated: 19 of the 20 patients were without visible parasites in the bone marrow; the mean time to afebrility was 4.2 days; spleen size regressed by a mean of 79% 2 months after therapy; and no patient had clinical or laboratory abnormalities by the end of 6-12 months of follow-up. Side effects were fever and chills accompanied by respiratory distress, but not nephrotoxicity, in children <3 years of age.
引用
收藏
页码:981 / 986
页数:6
相关论文
共 23 条
  • [1] ESTIMATION OF POPULATION AT RISK OF INFECTION AND NUMBER OF CASES OF LEISHMANIASIS
    ASHFORD, RW
    DESJEUX, P
    DERAADT, P
    [J]. PARASITOLOGY TODAY, 1992, 8 (03): : 104 - 105
  • [2] NEW PERSPECTIVES ON A SUBCLINICAL FORM OF VISCERAL LEISHMANIASIS
    BADARO, R
    JONES, TC
    CARVALHO, EM
    SAMPAIO, D
    REED, SG
    BARRAL, A
    TEIXEIRA, R
    JOHNSON, WD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (06) : 1003 - 1011
  • [3] TREATMENT OF VISCERAL LEISHMANIASIS WITH PENTAVALENT ANTIMONY AND INTERFERON-GAMMA
    BADARO, R
    FALCOFF, E
    BADARO, FS
    CARVALHO, EM
    PEDRALSAMPAIO, D
    BARRAL, A
    CARVALHO, JS
    BARRALNETTO, M
    BRANDELY, M
    SILVA, L
    BINA, JC
    TEIXEIRA, R
    FALCOFF, R
    ROCHA, H
    HO, JL
    JOHNSON, WD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) : 16 - 21
  • [4] VISCERAL LEISHMANIASIS IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
    BERENGUER, J
    MORENO, S
    CERCENADO, E
    DEQUIROS, JCLB
    DELAFUENTE, AG
    BOUZA, E
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) : 129 - 132
  • [5] BERMAN JD, 1988, REV INFECT DIS, V10, P560
  • [6] EFFECTS OF KETOCONAZOLE ON STEROL BIOSYNTHESIS BY LEISHMANIA-MEXICANA MEXICANA AMASTIGOTES IN MURINE MACROPHAGE TUMOR-CELLS
    BERMAN, JD
    GOAD, LJ
    BEACH, DH
    HOLZ, GG
    [J]. MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1986, 20 (01) : 85 - 92
  • [7] ACTIVITY OF AMPHOTERICIN-B CHOLESTEROL DISPERSION (AMPHOCIL) IN EXPERIMENTAL VISCERAL LEISHMANIASIS
    BERMAN, JD
    KSIONSKI, G
    CHAPMAN, WL
    WAITS, VB
    HANSON, WL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) : 1978 - 1980
  • [8] AN INVITRO MODEL FOR INVESTIGATION OF CHEMOTHERAPEUTIC-AGENTS IN LEISHMANIASIS
    BERMAN, JD
    WYLER, DJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1980, 142 (01) : 83 - 86
  • [9] A COMPARISON OF 3 DOSAGE REGIMENS OF SODIUM STIBOGLUCONATE IN THE TREATMENT OF VISCERAL LEISHMANIASIS IN KENYA
    CHULAY, JD
    BHATT, SM
    MUIGAI, R
    HO, M
    GACHIHI, G
    WERE, JBO
    CHUNGE, C
    BRYCESON, ADM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (01) : 148 - 155
  • [10] LIPOSOMAL AMPHOTERICIN-B IN DRUG-RESISTANT VISCERAL LEISHMANIASIS
    DAVIDSON, RN
    CROFT, SL
    SCOTT, A
    MAINI, M
    MOODY, AH
    BRYCESON, ADM
    [J]. LANCET, 1991, 337 (8749) : 1061 - 1062